Similar articles

• Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada.

  Sugimoto T, Nakamura T, Nakamura Y, Isogai Y, Shiraki M. Sugimoto T, et al. Osteoporos Int. 2014 Sep;25(9):2323-4. doi: 10.1007/s00198-014-2722-5. Epub 2014 May 8. Osteoporos Int. 2014. PMID: 24807627 Free PMC article. No abstract available.
• Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.

  Sugimoto T, Nakamura T, Nakamura Y, Isogai Y, Shiraki M. Sugimoto T, et al. Osteoporos Int. 2014 Mar;25(3):1173-80. doi: 10.1007/s00198-013-2516-1. Epub 2013 Oct 10. Osteoporos Int. 2014. PMID: 24108429 Free PMC article. Clinical Trial.
• Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

  Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ. Boonen S, et al. J Am Geriatr Soc. 2006 May;54(5):782-9. doi: 10.1111/j.1532-5415.2006.00695.x. J Am Geriatr Soc. 2006. PMID: 16696744 Clinical Trial.
• [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].

  Hashimoto Y, Wakayama N, Miyauchi A. Hashimoto Y, et al. Clin Calcium. 2007 Jan;17(1):48-55. Clin Calcium. 2007. PMID: 17211093 Review. Japanese.
• Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton.

  Sugiyama T, Kim YT, Oda H. Sugiyama T, et al. Osteoporos Int. 2015 Feb;26(2):443-7. doi: 10.1007/s00198-014-2923-y. Epub 2014 Oct 7. Osteoporos Int. 2015. PMID: 25288445 Review.